🧠 Anthem Biosciences IPO — “Bangalore’s BioBaba Wants Your Money”

📌 At a Glance

Anthem Biosciences Ltd is India’s fastest-growing CRDMO (Contract Research, Development, and Manufacturing Organisation). The company is coming up with a ₹3,395 Cr IPO — entirely Offer For Sale, so promoters are cashing out, not investing a rupee back. With ~550 clients globally, it operates across the drug lifecycle — from lab-to-launch, petri dish to patent. Financials are strong, margins are juicy, and customer base spans 44+ countries.

1. 🧪 WTF Does Anthem Even Do?

Anthem is basically the guy who:

• Helps you invent a new drug 🧫
• Helps you develop it 🧪
• Helps you make it at scale 🏭

A one-stop shop for CRDMO services. Which means:

• 🧠 Discovery services (170+ projects, 284 molecules synthesized)
• 🔬 Early & late phase R&D (16 late-stage projects, 13 commercial APIs)
• 🏭 Manufacturing: From biologics to fermentation-based APIs, peptides, probiotics, and even biosimilars

They’re also one of the few Indian players with strong biotech IP — with 7 global patents granted and 24 pending.

2. 💸 Financials: Show Me the Lab Money

Here’s how the bio-money has been flowing:

TL;DR:

• Profitable for years
• Margins